Within the 150 ALK-positive NSCLC patients dragonized in our hospital, 30 of them used second generation ALK inhibitors as the first TKI treatment (Supplementary Figure 1); however, the number of patients was limited and most of their clinical data have not matured. This evidence concerns the gene ALK and non-small cell lung carcinoma.